NTRK1 and thyroid gland carcinoma: So far, at least 58 receptor tyrosine kinases (RTKs) and 32 non-receptor tyrosine kinases (NRTKs) have been identified [29]. For advanced thyroid cancers, anti-angiogenic tyrosine kinase inhibitor drugs are the major targets [30].